While these studies focused upon the loss of mDia2 function and/or DIAPH3 expression, mDia2 agonism could impact tumor cells similarly, altering cells’ ability to drive cytoskeletal dynamics and execute downstream signaling through interacting partners. This evidence concerns the gene DIAPH3 and neoplasm.